Isocitrate dehydrogenase type 1 (IDH1) and IDH2 mutations are present in close to 60% of central cartilaginous tumors: the former is present in 50–55% with IDH2 alterations being detected in ~6% of central lesions 12. This evidence concerns the gene IDH2 and chondrogenic neoplasm.